



A NEHI Roundtable

The Alzheimer's Disease Patient Journey: Pathways to Early-Stage Screening and Detection

Date: Thursday, May 23, 1:00 5:00 PM ET

Venue:

- In Person: Kaiser Permanente Center for Total Health, 700 2nd Street NE, Washington DC 20002
- Virtual: [Join the meeting now](#) | Meeting ID: 269 722 150 097 | Passcode: LkcmGF

Agenda

1:00 PM – Lines open for virtual participants

1:15 PM – Welcome and Opening Presentation, Tom Hubbard, NEHI

1:30 PM – **Panel #1: Oncoming Innovations for Screening and Assessment of Mild Cognitive Impairment and Dementia** (Moderator: Tom Hubbard, Senior Vice President of Policy Research, NEHI)

Panelists:

- Deborah E. Barnes, PhD, MPH, Professor, Departments of Psychiatry and Behavioral Sciences and Epidemiology & Biostatistics, UCSF Weill Institute for Neurosciences and Osher Center for Integrative Health, University of California, San Francisco
- David Bates, PhD, CEO & Co-Founder, Linus Health
- James Hendrix, PhD, Executive Director for U.S. Medical Affairs, Eli Lilly & Co.
- Todd Levine, MD, Chief Medical Officer & Co-Founder, CND Life Sciences
- Joshua Soldo, Chief Scientific Officer & Co-Founder, Veravas, Inc.

3:00 PM – Break

3:10 PM – **Panel #2: Implications for Clinical Practice and Health Care Policy of Oncoming Innovations in MCI and Dementia Screening and Assessment** (Moderator: Tom Hubbard)

Panelists:

- Amanda Bartelme, Executive Director, Policy, Eisai, Inc.
- Angela Hsu, MD, Physician Director of Memory Care Services, Mid-Atlantic Permanente Medical Group
- Ian N. Kremer, JD, Executive Director, LEAD (Leaders Engaged on Alzheimer's Disease) Coalition
- Scott Sarran, MD, MBA Chief Medical Officer, Harmonic Health
- Karen Tracy, Vice President of Strategic Alliances & Integrated Communications, Gerontological Society of America
- Julie K. Wood, MD, MPH, FAFAP, Senior Vice President of Science and Clinical Strategy, American Academy of Family Physicians; Family Physician

4:40 PM – Concluding Remarks

4:45 PM – Close

The Alzheimer's Disease Patient Journey: Pathways to Early-Stage Screening and Detection

Thursday, May 23, 1:00 PM - 4:45 PM ET
Kaiser Permanente Center for Total Health

Thomas E. Hubbard, MPP (Moderator)

Senior Vice President of Policy Research, Network for Excellence in Health Innovation (NEHI)

Tom Hubbard leads NEHI's projects on coverage and payment for innovative biopharmaceuticals, comparative effectiveness research policy, Real World Evidence, medication management, and patient medication adherence. Mr. Hubbard leverages his policy and technology experience to examine ways the country's healthcare system can be transformed, focusing on the promotion of medical innovation and the improvement of quality and efficiency in clinical care.

Mr. Hubbard came to NEHI after seven years at the Massachusetts Technology Collaborative (MTC), where he led industry-focused projects and supervised the annual publication of the MTC Index of the Massachusetts Innovation Economy. His work has included supervising the I-495 Technology Corridor Partnership, an industry-municipal collaboration on growth, and leading projects on broadband deployment, federal research funding advocacy, and nanotechnology.

Previously, Mr. Hubbard served as Executive Assistant for Economic Affairs to U.S. Senator John Kerry, as Deputy Director of Development for Massachusetts Governor Michael Dukakis, and as Director of Community Development and Planning for the City of Gardner, Massachusetts.

Mr. Hubbard graduated from Harvard College and holds a Master's in public policy from Harvard's Kennedy School of Government.



Panel One

Oncoming Innovations for Screening and Assessment of Mild Cognitive Impairment and Dementia

Deborah E. Barnes, PhD, MPH

Professor, Departments of Psychiatry and Behavioral Sciences and Epidemiology & Biostatistics, UCSF Weill Institute for Neurosciences and Osher Center for Integrative Health, University of California, San Francisco

Dr. Barnes is internationally recognized as an expert in the epidemiology of dementia. She has co-authored more than 150 peer-reviewed publications, including many in high-impact journals such as JAMA and Lancet Neurology. In addition, she has received independent research funding from the National Institutes of Health, Department of Veterans Affairs, Department of Defense, and Alzheimer's Association, among others. She has broad expertise in the design, conduct, and analysis of observational studies, clinical trials, and implementation studies. Her research focuses on 1) identifying modifiable risk factors for cognitive impairment and dementia in older adults; 2) developing risk prediction models to identify high-risk individuals and to forecast the potential impact of risk reduction strategies; and 3) developing and testing interventions to delay the onset and slow progression of symptoms.



David Bates, PhD

CEO & Co-Founder, Linus Health

David is the CEO and co-founder of Linus Health. He is a scientist, engineer, inventor, entrepreneur, and investor. David was a founding partner of Tamarisc Ventures and co-founded Bode, a tech-enabled hospitality company for group travel. He is on the board of several technology companies and the philanthropic TMCity Foundation. David has previously held positions at Morningside Ventures, F-Wave, Harvard Medical School, Massachusetts General Hospital, University of Louisville, and Georgia Tech. David earned his Ph.D. in Chemical and Materials Engineering from the University of Auckland and his BS and MSc in Applied Biology from the Georgia Institute of Technology. He resides in Boston with his wife and kids.



James Hendrix, PhD

Executive Director for US Medical Affairs, Eli Lilly & Company

Jim Hendrix received his Ph.D. and a postdoctoral fellowship in organic chemistry from Colorado State U. He started his pharmaceutical career as a medicinal chemist at Hoechst-Roussel (later Sanofi-Aventis) working in CNS drug discovery. Jim worked for the company for 18 years rising to the level of Senior Director, U.S. Site Head for CNS Research. Jim also spent 2 years in biotech with various companies before joining the Alzheimer's Association in Chicago as Director of Global Science Initiatives. In 2018, Jim became the Chief Scientific Officer for LuMind IDSC, a non-profit focused on Down syndrome research. In April of 2022, Jim joined Eli Lilly and Company as Executive Director for US Medical Affairs working in the Neuroscience Business Unit acting as a clinical research scientist.



Todd Levine, MD

*Chief Medical Officer & Co-Founder, CND Life Sciences
Clinical Neurologist*

Dr. Todd Levine is one of the three founders of CND Life Sciences and serves as its Chief Medical Officer, playing a key role in the delivery of diagnostic services and ongoing technology development. Dr. Levine also serves as the Director of Neuroscience Research at HonorHealth Research Institute and has over 25 years of experience as a clinical neurologist with a sub-specialty in disorders of the peripheral nervous system. In 2010, he founded his first medical diagnostics company called Corinthian Reference Lab (CRL). Based in Fort Worth, Texas, CRL has processed over 50,000 skin biopsies, receiving specimens from over 4,000 different neurologists across the US and Canada. He received his medical degree from Duke University and did his residency and fellowship at Washington University in St Louis. He has served as the Chairman of the Neuromuscular Division of the American Academy of Neurology and has served as the Medical Director of Neurology for HonorHealth in Phoenix, Arizona.



Joshua Soldo

Chief Scientific Officer & Co-Founder, Veravas, Inc.

Joshua Soldo is a healthcare innovator who has dedicated his career to developing diagnostic tests with the mission of giving patients a greater chance of survival and reducing the number of preventable medical tragedies. He has over 25 years of experience in diagnostic technology, product development, and commercialization in the IVD and life sciences industries, and he is a subject matter expert in solid phase chemistry, sample interference, and biomarker testing. He is a sought-after speaker and educator, and his research and patent portfolio include six granted US patents and over 40 international patents. His expertise in assay development and solid phase chemistry has been instrumental in his invention of Veravas's proprietary magnetic bead technology, VeraBIND (Biomarker Isolation and N-richment for Detection), for sample interference elimination and biomarker purification and enrichment. He has held numerous R&D and Scientific Affairs leadership roles over the past 20 years at Roche Diagnostics, Anteo Technologies, DiaSorin, and Beckman Coulter. He was the recipient of the 2017 Roche Career Achievement Award for demonstration of continued commitment and achievement of excellence within Medical & Scientific Affairs, and the 2006 Beckman Coulter "Innovation in Technology" corporate award for his research to improve the quality and manufacturing scale of the Access immunoassays. At DiaSorin his teams developed and commercialized the market leading LIAISON 25 OH Vitamin D Total Assay, and he was the principal inventor of the world's first fully automated, extraction free immunoassay for the accurate detection of 1,25 Dihydroxyvitamin D. Josh's vision for Veravas is to continue leveraging its innovative VeraBIND technology platform to develop better diagnostics tools for Alzheimer's and other neurodegenerative diseases, ultimately improving patient care. His leadership is playing a major role in the company's success and has enabled Veravas to provide tools supporting the development of assays with unparalleled accuracy and sensitivity.



Panel Two

Implications for Clinical Practice and Healthcare Policy of Oncoming Innovations in Mild Cognitive Impairment and Dementia Screening and Assessment

Amanda Bartelme

Executive Director, Policy, Eisai, Inc.

Amanda Bartelme serves as Executive Director of Policy at Eisai, Inc. In this role, she leads Eisai's engagement with the Centers for Medicare and Medicaid Services (CMS), focusing on ensuring Medicare beneficiaries have appropriate access to treatments. Ms. Bartelme also provides internal support on issues related to access, reimbursement, and drug pricing, and represents Eisai in workgroups with PhRMA and BIO focused on these areas.

Prior to joining Eisai in May 2022, Ms. Bartelme was Director of Coding and Reimbursement, US Public Policy at GSK, where she supported access to vaccines, oncology, respiratory, rheumatology, HIV, and Covid treatments. She also served as Associate Director of Policy and Reimbursement at Baxalta, where she focused on hemophilia, oncology, and plasma-based therapies. Ms. Bartelme began her career in health policy and reimbursement at Avalere Health, where she spent over a decade working on access for drugs, devices, and services with a special focus on physician-administered drugs, diabetes, biosimilar payment policy, the 340B program, and the evolving drug pricing and payment landscape.

Ms. Bartelme earned her Bachelor of Science degree from Cornell University. She has authored articles published in *The Journal of Diabetes Science and Technology*, as well as *Diabetes Therapeutics & Technology*.



Angela Hsu, MD

Physician Director of Memory Care Services, Mid-Atlantic Permanente Medical Group

Dr. Angela Hsu is board-certified in internal medicine and geriatrics and currently practicing in Northern Virginia in the Mid-Atlantic Permanente Medical Group's Memory Care Program, leading an interdisciplinary team as the Physician Director for Memory Care Services. In addition to being a front-line geriatrician focused on memory care, Dr. Hsu is involved in geriatric strategy development at MAPMG, including program innovation and education to improve systems of care for our older patients.

Dr. Hsu graduated from the Columbia University College of Physicians and Surgeons, completed her internal medicine residency at Columbia University Medical Center in New York City, and fellowship training in geriatrics at the University of California, San Francisco. Prior to joining MAPMG in 2014, Dr. Hsu worked as a physician in the PACE (Program for All-Inclusive Care of the Elderly) at Cambridge Health Alliance, a community-focused healthcare provider in Cambridge, MA, and an instructor in geriatrics for medical students and residents at Harvard Medical School.



Ian N. Kremer, JD

Executive Director, LEAD (Leaders Engaged on Alzheimer's Disease) Coalition

Ian N. Kremer, JD, has worked on federal, state, and local dementia policy since 1996. Since 2012, Kremer has served as Executive Director of the LEAD Coalition (Leaders Engaged on Alzheimer's Disease: <http://www.leadcoalition.org>), the uniting voice of over 200 member and allied organizations. The LEAD Coalition accelerates transformational progress in care and support to enrich the quality of life of those with dementia and their caregivers, detection and diagnosis, and research leading to prevention, effective treatment, and cures. The LEAD Coalition has helped to secure historic funding increases for the National Institutes of Health (NIH), expand Medicare services for people with dementia and protect dementia-relevant components of Medicaid and the Patient Protection and Affordable Care Act, expand the role of people with dementia and their care partners in medical product development, build a nation-wide network of dementia-friendly communities, work with a dozen federal agencies to overcome health disparities, clarify regulatory pathways, combat elder abuse, and improve cognitive impairment detection and diagnosis, clinical care, and access to home and community-based services.



Scott Sarran, MD, MBA

Chief Medical Officer, Harmonic Health

Scott Sarran, MD, MBA, has over 30 years of leadership experience in managed care and population health on both the provider and payer sides. A graduate of Northwestern University (undergraduate, medical, and business schools), he is board-certified in both Family Medicine and Geriatrics. The central focus of his career has been on creating value for patients, providers, and payers by clinical re-design linked to a granular understanding of business realities, thereby enabling successful payer-provider risk arrangements across commercial and especially government programs (both Medicaid and Medicare). He is currently serving as a Medicare Payment Advisory (MedPAC) Commissioner, a role in which he contributes to the variety of publications and recommendations MedPAC delivers to Congress regarding the Medicare Program. In addition, he serves as Chief Medical Officer for Harmonic Health, a start-up Care Management enablement company supporting providers and caregivers in the Dementia space. He has served in a variety of Chief Medical Officer roles on the Payer side, including large companies (Blue Cross Blue Shield IL, Health Care Services Corporation, for Government Programs), and small start-ups (MoreCare IL, Fidelis Senior Care, including Special Needs Plans [SNPs]). He has also served in Chief Medical Officer roles on the Provider side (Advocate Health Centers, Cook County Health, for Population Health).



Karen Tracy

*Vice President of Strategic Alliances & Integrated Communications,
Gerontological Society of America*

Karen Tracy is Vice President of Strategic Alliances and Integrated Communications at the Gerontological Society of America (GSA). Her responsibilities at GSA include overseeing the Society's multi-stakeholder collaborations such as the National Adult Vaccination Program, the Brain Health, Cognitive Impairment, and Dementia Initiative, the Obesity and Overweight Initiative, the Oral Health as an Essential Element of Health Aging Initiative, the Corporate Leaders Forum, and others. She also serves on the senior leadership team that establishes organizational policy and presents to the GSA Board of Directors on budget, strategic planning, and performance. For 18 years, Tracy held various leadership positions at the American Pharmacists Association (APhA) and concluded her tenure as the senior vice president of a \$10 million integrated communications and information division and member of the APhA senior management team. Prior to joining APhA, she served as vice president at Trinity Communications and VoxMedica, both healthcare communication firms based in Philadelphia. Tracy holds a Bachelor of Science degree in economics and a minor in political science from the University of Delaware.



Julie K. Wood, MD, MPH, FAAFP

*Senior Vice President of Science and Clinical Strategy, American Academy of Family Physicians
Family Physician*

Julie K. Wood, MD, MPH, FAAFP, is a family physician and serves as Senior Vice President of Science and Clinical Strategy for the American Academy of Family Physicians (AAFP).

Dr. Wood provides oversight for the scientific and research activities of the AAFP, as well as the AAFP's relationships with other organizations in the United States and abroad. Wood oversees AAFP efforts to provide family physicians with evidence-based clinical guidance on topics including global health, rural health, and maternal and child health.

Prior to joining the AAFP staff in 2013, Wood was a practicing family physician for nearly 20 years, starting out as a solo rural family physician in her hometown of Macon, Missouri and then became residency faculty at the Research Family Medicine Residency Program in Kansas City.

Wood earned her undergraduate and medical degrees from the University of Missouri-Kansas City. She then completed her residency at Via Christi-St. Francis Family Medicine Residency Program in Wichita, Kansas. She earned her master's degree in public health from the University of West Florida. She is board-certified by the American Board of Family Medicine and has the AAFP Degree of Fellow.



Thank you to our Project Sponsors!

